Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 12/20 | 0.61 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538286 | 0.83 | CCR3 (0.62) | CCR3 | |
| SCHEMBL2567265 | 0.77 | CCR3 (0.56) | CCR3 | |
| SCHEMBL10396359 | 0.69 | KHK (0.54) | KHK | |
| Hydrochloric Acid SCHEMBL10395959 | 0.68 | KHK (0.53) | KHK | |
| SCHEMBL9150735 | 0.68 | REN (0.39) | HTR1ASLC6A2SLC6A4SLC6A3KHK | |
| SCHEMBL2567532 | 0.67 | HTR6 (0.58) | CCR3HTR6 | |
| SCHEMBL9150837 | 0.66 | HTR6 (0.40) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL373751 | 0.64 | HTR6 (0.69) | CCR3SLC6A4HTR6 | |
| SCHEMBL22760096 | 0.64 | REN (0.39) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL22491537 | 0.64 | APP (0.66) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1994019-B1 | NOVEL PIPERIDIN - SUBSTITUTED INDOLES AND THEIR USE AS CCR-3 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247230-A1 | Novel Piperidine-Substituted Indoles | CCR3, CCR1, CCR2 | CCR3 1/4885HTR1A 150/4885SLC6A2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.